- Current report filing (8-K)
March 18 2011 - 4:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 14, 2011
Impax Laboratories, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-34263
|
|
65-0403311
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
30831 Huntwood Avenue, Hayward, CA
|
|
94544
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(510) 476-2000
|
Not Applicable
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.02
|
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
|
On March 14, 2011, the Board of Directors (the Board) of Impax Laboratories, Inc. (the Company) promoted
Arthur A. Koch, Jr., to the position of Executive Vice President, Finance. In 2005, Mr. Koch, age 57, joined the
Company as Senior Vice President, Finance and Chief Financial Officer. Mr. Koch will continue as Chief Financial
Officer. The Board did not make any changes to Mr. Kochs existing employment agreement with the Company in connection
with his change in title.
On March 14, 2011, the Compensation Committee (the Committee) of the Board approved (i) cash incentive awards
for the Companys current named executive officers, as defined in Item 402 of Regulation S-K (the Named Executive
Officers), for 2010 performance, and (ii) the 2011 cash incentive award plan.
The following table presents the cash incentive awards paid in 2011 for the 2010 performance of the Named
Executive Officers:
|
|
|
|
|
|
|
2010 Cash
|
|
|
|
Incentive Award
|
|
Name
|
|
($)
|
|
Larry Hsu, Ph.D.
President and Chief Executive Officer
|
|
|
546,000
|
|
Arthur A. Koch, Jr.
Executive Vice President, Finance and Chief Financial Officer
|
|
|
275,010
|
|
Michael J. Nestor
President, Impax Pharmaceuticals division
|
|
|
264,697
|
|
Charles V. Hildenbrand
Senior Vice President, Operations
|
|
|
178,602
|
|
Under the 2011 cash incentive award plan, the Named Executive Officers have the opportunity to receive a cash
incentive award calculated as a percentage of base salary based upon the achievement of certain corporate and
individual performance goals. For 2011, the corporate performance goals will be based upon one or more of the
following measures as determined by the Committee: an internal net sales target, an internal net income target and an
internal EBITDA target. The individual performance goals will be comprised of objectives specific to the functional
area for which each Named Executive Officer has responsibility, as determined by the Committee. The table below
provides the 2011 cash incentive award targets for the Named Executive Officers and the relative weighting of each
targeted performance criteria, as applicable:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2011 Cash
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
Maximum Target
|
|
|
|
|
|
|
Award
|
|
|
for 2011 Cash
|
|
|
|
|
|
|
Target
|
|
|
Incentive Award
|
|
|
|
|
Name
|
|
(%)
|
|
|
(%)
|
|
|
Performance Criteria
|
|
Larry Hsu, Ph.D.
|
|
|
80
|
|
|
|
120
|
|
|
95% Corporate Goals
and 5% Individual Goals
|
Arthur A. Koch, Jr.
|
|
|
60
|
|
|
|
90
|
|
|
85% Corporate Goals
and 15% Individual Goals
|
Michael J. Nestor
|
|
|
60
|
|
|
|
90
|
|
|
85% Corporate Goals
and 15% Individual Goals
|
Charles V. Hildenbrand
|
|
|
60
|
|
|
|
90
|
|
|
85% Corporate Goals
and 15% Individual Goals
|
1
2
The Committee has the discretion to pay at, above or below the percentage targets set forth in the column 2011
Cash Incentive Award Target in the table above depending on the Companys overall financial and operational
performance and each Named Executive Officers individual performance. The percentage targets in the column Maximum
Target for 2011 Cash Incentive Award represent maximum percentages of the executives respective 2011 base salaries
that the Company can award for superior performance.
Further, Dr. Hsu and Messrs. Koch and Nestor will have the opportunity to receive an additional 2011 cash
incentive award tied to incremental improvements in safety and quality in the Companys manufacturing operations as
measured by the Companys achievement of internal quality initiative targets, as determined by the Board. The award
opportunities upon the Companys achievement of the quality initiative targets are as follows: (i) Dr. Hsu, $300,000;
(ii) Mr. Koch, $150,000; and (iii) Mr. Nestor, $150,000.
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 18, 2011
IMPAX LABORATORIES, INC
.
By:
/
s/ Arthur A. Koch, Jr.
Name: Arthur A. Koch, Jr.
Title: Executive Vice President, Finance and
Chief Financial Officer
3
4
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024